Eledon Pharmaceuticals, Inc. on January 13, 2025, provided a summary of its 2024 accomplishments and outlined anticipated business milestones for 2025. The company completed enrollment in its Phase 2 BESTOW trial for kidney transplantation four months ahead of schedule, with topline results expected in the fourth quarter of 2025.
Updated data from 13 participants in the ongoing Phase 1b trial continued to support the safety and tolerability of tegoprubart for preventing organ rejection in kidney transplantation. Additionally, positive initial data was announced from the first three subjects treated with tegoprubart in an investigator-initiated islet transplantation trial for type 1 diabetes.
The company also completed two financings totaling $135 million in combined gross proceeds during 2024, which are expected to support operations through the end of 2026. These achievements position Eledon for a pivotal year ahead, with significant data readouts anticipated.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.